Using Truveta Data, we sought to answer a few simple but timely questions: who is receiving the oral semaglutide pill in the first weeks following FDA approval, what provider types are prescribing these drugs, and are these patients new GLP-1-therapy initiators or patients switching from an existing prescription
A RECENT study has identified a potential link between the use of semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), and an increased risk of developing nonarteritic anterior ischemic optic neuropathy (NAION) in patients with type 2 diabetes (T2D) or those who are overweight or obese
Effects on gene activation, transcription, protection of genes involved in methylation, and numerous other functions indicate a tantalizing menu of therapeutic possibilities
What Ozempic and Keto Actually Do You've likely heard a lot about Ozempic and the ketogenic dietand with all the buzz, it's easy to feel curious or confused